FDA Ponders Trimming PDUFA Programs
This article was originally published in The Tan Sheet
Executive Summary
Acting Commissioner Ostroff considers whether all aspects of the user fee program are delivering maximum added value.
You may also be interested in...
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
FDA wants to advance PRO projects through the user fee reauthorization, but ironically is having difficulty quantifying how much support it might need.
‘Breakthrough’ Fee Eyed As Deterrent To Frivolous Requests
Companies currently face little risk in seeking the designation because there is no financial cost and FDA denial is confidential.
FDA Staying The Course Under Ostroff; Hamburg’s Concerns Will Remain Focus
Acting FDA Commissioner says he can’t envision any new major priorities that would emerge in the short-term.